Research Article

Neonatal Screening for Sickle Cell Disease in Congo

Alexis Elira Dokekias,1,2 Lethso Thibaut Ock Ogo Gokaba,1,2 Josué Simo Louokdom,1 Lydie Ngolet Ocini,1,2 Firmine Olivia Galiba Atipo Tsiba,1,2 Coreillia Irène Ondzotto Ibatta,1 Quentin Ngoma Kouandzi,1 Serge Talomg Tamekue,1 Jayne Chelsea Bango,1 Jade Vanessa Nziengui Mboumba,1 and Simon Charles Kobawila2

1Centre National de Référence de la Drépanocytose “Antoinette SASSOU N’GUÉSSO, Brazzaville, Congo
2Université Marien Ngouabi, Brazzaville, Congo

Correspondence should be addressed to Alexis Elira Dokekias; arian.mouhani@gmail.com

Received 26 May 2021; Revised 21 November 2021; Accepted 7 January 2022; Published 3 February 2022

Academic Editor: Duran Canatan

Copyright © 2022 Alexis Elira Dokekias et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Sickle cell disease is an autosomal recessive inherited disorder due to the mutation of a gene coding for the globin beta chain. The aim of this study is to update the epidemiological data on hemoglobinoses, in particular sickle cell disease in newborns in Congo. Materials and Methods. This was a descriptive cross-sectional study, conducted from October 1, 2019, to March 31, 2020, throughout the Congolesse national territory. It involved all full-term newborns, without distinction of nationality, aged 5 days or less, and whose parents consented to participate in the study. The blood samples, taken at the heel and collected on Whatman blotting paper, were analyzed using the HPLC Variant NBS machine. Results. In 2897 newborns (NN) screened, hemoglobin abnormalities were found in 603 NN (20.81%). The mean age of these newborns was 1 day (extremes 0 and 5 days). The male-to-female ratio was 1.03. Abnormal hemoglobins were mainly Hb S (n = 597 (97.71%)); Hb C (n = 5 (0.82%)); and variants (n = 7 (1.15%)). The prevalence of major sickle cell (MSC) syndromes and sickle cell trait was 1.35% and 19.43%, respectively. The prevalence ranged from 1.77% to 2.56% for MSS in four departments and from 20.5% to 25.8% for the sickle cell trait in six other departments. Conclusion. Data on homozygous sickle cell disease remain consistent with previous studies. However, further studies should clarify the molecular anomalies of the variants observed in our samples.

1. Introduction

Sickle cell disease is an autosomal recessive inherited disorder linked to the mutation of a gene coding for the beta chain of globin [1–3].

It is the first genetic disease in the world which mainly comprises four (4) primitive foci: African focus, Asian Peninsula, South-East Asia, and an incidental focus in the Balkans.

A distinction is made between heterozygous forms (AS) and homozygous forms (SS) which are part of the major sickle cell syndromes (MSS). The major sickle cell syndromes include the following entities: homozygous abnormal hemoglobin S, hemoglobin S associated with other abnormalities (C, D, and O), and intermediate forms of thalassemia. Multiple studies have been carried out worldwide on the prevalence of this genetic disorder [4–9]. In Africa, studies report a prevalence of 0.8 to 3% of major forms and 7 to 24% of heterozygous forms [4, 5, 10–16]. Studies in Congo have involved local sampling and analysis, most often carried out outside Congo [4, 16]. These analyses placed the frequency of sickle cell trait in Congo between 19 and 24% and the homozygous form around 1% according to neonatal samples [4, 16].

This study, which focuses on neonatal sampling, was conducted entirely in Congo. The samples were taken from newborns in all departments of the Republic of Congo, and the analyses were carried out on site. In order to update the data on sickle cell disease in Congo, we conducted this study to determine the prevalence of sickle cell disease and to
estimate the variants of hemoglobin (Hb) in newborns in each department of Congo.

2. Materials and Methods

This was a cross-sectional descriptive study conducted from 1 October 2019 to 31 March 2020 over the entire national territory of Congo (Figure 1). The Republic of Congo is located in sub-Saharan Africa, in the sickler belt. It is made up of 12 departments (Figure 1) in which samples were collected and sent to the Centre National de Reference de la drepanocytose (CNRDr) for analysis. The CNRDr is a subregional facility, open to the public in 2016, specialising in the management of genetic diseases including sickle cell disease. It comprises care, imaging, and medical biology units.

The target population consists of full-term newborn babies (NBs) born in the Congolese territory. All NBs without distinction of nationality, aged 5 days or less, were included in the study. We did not include all NBs in the posttransfusion period and those in intensive care. Furthermore, only the NBs whose parents had given their informed consent were included. Only those whose parents gave consent were screened. Refusal to screen a newborn was a criterion of exclusion. The recruitment was carried out in a comprehensive way.

Considering the prevalence of the sickle cell trait of 21% [17] and the effect of the sampling design set at 1.5 and the imponderables estimated at 5%, the minimum sample size required for this study is 406. The number 406 corresponds to the minimum of patients needed to carry-on the study. It is not the sample of our study but the minimum required. The minimum sample size for each department (cluster) was calculated by weighting the national minimum baseline sample size (406 NBs) according to the size of the population in the department. By rounding up these numbers, the minimum sample size selected was 412, broken down by department (Table 1).

For each newborn baby, a drop of blood was collected at the heel on Whatman 903TM (903 protein saver card) blotting paper under aseptic conditions. The samples were stored for a maximum of 72 hours in pouches (Multi-Barrier Pouches) with desiccant from GE Healthcare company laboratories. They were analyzed using the cation exchange high-performance liquid chromatography (HPLC) procedure (BioRad Variant NBS). Patient profiles were obtained by ranking hemoglobins in descending order of magnitude (thus, an FSA profile assumes a hemoglobin F concentration greater than hemoglobin S concentration and the latter greater than hemoglobin A concentration). The chromatographic profile of MSS was established in the presence of Hb: F, FS, FSC, FSE, FSD, FSA, FSE, and FSa.

The data obtained were entered and processed using Microsoft Excel version 17.2 and R 3.6.3 software [18]. Qualitative variables were presented as numbers and percentages. Ethical clearance was obtained from the Comité Ethique de Recherche en Science de la Santé (CERSSA).

3. Results

At the end of this study, we obtained a total of 2,897 newborns, 603 of whom had abnormal hemoglobins, being 20.81%. The mean age of these newborns was one (01) day with extremes ranging from 0 to 5 days and a sex ratio (F/M) of 1.03. They were born at 38 (q1 36–q3 39) weeks of amenorrhea with an average weight of 3114±567 g.

Figure 1 illustrates the prevalence of abnormal hemoglobin in newborns by department.

The abnormal hemoglobin found were Hb S (n = 597; 97.71%), Hb C (n = 5; 0.82%), Hb D (n = 1; 0.16%), Hb E (n = 1; 0.16%), Hb Bart (n = 1; 0.16%), and unidentified Hb (n = 7; 1.15%). The distribution of the different types of abnormal hemoglobin by department is described in Table 2.

Among the 2,897 newborns registered, major sickle cell syndrome (MSS) was found in 39 NBs and the sickle cell trait was found in 563, representing national prevalences of 1.35% and 19.43%, respectively (Table 3).

Heterozygous qualitative hemoglobin abnormalities were AS (n = 551 (97.87%)) and AC (n = 5 (0.89%)).

Table 4 reports the prevalence of the sickle cell trait and MSS phenotypes according to the departments of Congo.

4. Discussion

This study’s objective was to update the epidemiological data on sickle cell disease in Congo. The systematic screening approach was favored over the approach targeting NBs from parents with a family history of sickle cell disease, firstly, because healthy AS carriers do not express the disease and are often unaware of their status, which makes it difficult to identify subjects at risk and, secondly, because of the high prevalence of the S gene in the Congo Basin. This screening was carried out using the HPLC variant NBS technique, which has the advantage of being fully automated but also has a high sensitivity to detect normal neonatal hemoglobins (Hb F and Hb A) and the main hemoglobin variants (Hb S, C, E, and D).

In our study, the sex ratio (1.03), in favour of men, was similar to that reported in the literature [5, 13, 14, 19–21]. The average weight of newborns with abnormal hemoglobins was comparable to observations made by Munyanganzizi in Rwanda and Kafando in Burkina Faso [10, 19]. It was lower than the one reported by McGann in Angola, which found an average weight of 3.201±526 g [15]. Dietary, environmental, and genetic factors could explain these differences.

The prevalence of abnormal hemoglobin was 20.8%, mainly represented by hemoglobin S (97.71%). The geographical location of the Republic of Congo in the sickler belt and the endemic nature of malaria in Congo could be one of the factors favoring this condition. Indeed, in order to better resist malaria, the populations of this region have undergone mutations that have led to the appearance of hemoglobin S. Subjects carrying this mutation in its heterozygous form present a certain resistance to Plasmodium...
A selective pressure with the evolution of the disease would have contributed to the increase in its prevalence. Results found in the literature indicate abnormal hemoglobin frequencies ranging from 0.22% to 31% [4, 5, 9, 13, 20, 23–25]. Some of these observations are comparable to ours [4, 5]; on the other hand, others had different results from ours [9, 13, 20, 23–25]. Results comparable to ours can be justified by the fact that these studies were carried out in Central Africa in the Congo Basin, the epicenter of sickle cell disease as in our case [4, 5, 22]. The results differing from ours can be explained by the fact that these screenings were carried out in non-endemic or low-malaria-endemic areas where sickle cell disease cases are mainly imported cases or from families with

Table 1: Minimum sample size by department.

| Department     | Population census of 2007 | Minimum newborn size to be tested | Number of newborns tested |
|----------------|---------------------------|----------------------------------|---------------------------|
| Brazzaville    | 1733271                   | 151                              | 1560                      |
| Pointe Noire   | 902828                    | 79                               | 370                       |
| Bouenza        | 390032                    | 34                               | 113                       |
| Pool           | 298580                    | 26                               | 132                       |
| Niari          | 291865                    | 26                               | 179                       |
| Plateaux       | 220328                    | 20                               | 121                       |
| Cuvette        | 196930                    | 18                               | 124                       |
| Likouala       | 194507                    | 17                               | 60                        |
| Lekoumou       | 121639                    | 11                               | 54                        |
| Kouilou        | 116065                    | 11                               | 38                        |
| Sangha         | 108211                    | 10                               | 68                        |
| Cuvette-Ouest  | 92123                     | 9                                | 78                        |
| Total          | 4666379                   | 412                              | 2897                      |

Figure 1: Prevalence of abnormal hemoglobin in newborns in the departments of Congo.
relatives from highly endemic areas. This justifies the need for the establishment of a national program of systematic screening for sickle cell anemia in order to provide early management of newborns living with sickle cell anemia. Moreover, early management makes it possible not only to delay the onset of complications but also to undertake

**Table 2: Distribution of abnormal hemoglobins (Hb) in NBs by department between November 2019 and March 2020.**

| Department     | HbS, n (%) | Autre Hb*, n (%) | HbC, n (%) | HbE, n (%) | HbBart, n (%) | HbD, n (%) |
|----------------|------------|------------------|------------|------------|---------------|------------|
| Bouendza       | 15 (2.5)   | 2 (28.6)         | —          | —          | —             | 1 (100)    |
| Brazzaville    | 314 (52.6) | 1 (14.3)         | 5 (100)    | —          | 1 (100)       | —          |
| Cuvette Centrale | 32 (5.4)   | 1 (14.3)         | —          | —          | —             | —          |
| Cuvette-Ouest  | 18 (3.0)   | —                | —          | —          | —             | —          |
| Kouilou        | 4 (0.7)    | —                | —          | —          | —             | —          |
| Lekoumou       | 12 (2.0)   | —                | —          | —          | —             | —          |
| Likouala       | 6 (1.0)    | —                | —          | —          | —             | —          |
| Niari          | 46 (7.7)   | 2 (28.6)         | —          | —          | —             | —          |
| Plateau        | 23 (3.9)   | —                | —          | —          | —             | —          |
| Pointe Noire   | 90 (15.1)  | —                | —          | 1 (100)    | —             | —          |
| Pool           | 31 (5.2)   | 1 (14.3)         | —          | —          | —             | —          |
| Sangha         | 6 (1.0)    | —                | —          | —          | —             | —          |
| Total          | 597 (100)  | 7 (100)          | 5 (100)    | 1 (100)    | 1 (100)       | 1 (100)    |

n: number; *: unidentified Hb variant.

**Table 3: Prevalence of sickle cell disease among newborns according to the departments of Congo between November 2019 and March 2020.**

| Department     | Total, n (%) | Carrier Hb AA, n (%) | Carrier Hb AS/AC, n (%) | MSS*, n (%) |
|----------------|--------------|----------------------|-------------------------|------------|
| Bouendza       | 113 (3.90)   | 98 (86.7)            | 13 (11.5)               | 2 (1.77)   |
| Brazzaville    | 1560 (53.8)  | 1241 (79.6)          | 298 (19.1)              | 21 (1.35)  |
| Cuvette Centrale | 124 (4.28)  | 92 (74.2)            | 32 (25.8)               | —          |
| Cuvette-Ouest  | 78 (2.69)    | 60 (76.9)            | 16 (20.5)               | 2 (2.56)   |
| Kouilou        | 38 (1.31)    | 34 (89.5)            | 4 (10.5)                | —          |
| Lekoumou       | 54 (1.86)    | 42 (77.8)            | 12 (22.2)               | —          |
| Likouala       | 60 (2.07)    | 54 (90.0)            | 6 (10.0)                | —          |
| Niari          | 179 (6.18)   | 133 (74.3)           | 44 (24.6)               | 2 (1.12)   |
| Plateau        | 121 (4.18)   | 98 (81.0)            | 22 (18.2)               | 1 (0.83)   |
| Pointe Noire   | 370 (12.8)   | 280 (75.7)           | 81 (21.9)               | 9 (2.43)   |
| Pool           | 132 (4.56)   | 101 (76.5)           | 29 (22.0)               | 2 (1.52)   |
| Sangha         | 68 (2.35)    | 62 (91.2)            | 6 (8.82)                | —          |
| Total          | 2897 (100)   | 2295 (79.21)         | 563 (19.43)             | 39 (1.35)  |

* MSS: major sickle cell syndrome (FS, FSE, and FSA).

**Table 4: Distribution of abnormal Hb chromatographic profiles in newborns according to departments between November 2019 and March 2020.**

| Department     | Heterozygous profile | MSS profile |
|----------------|----------------------|-------------|
|                | FAC, n (%) | FS, n (%) | FSA**, n (%) | FSE, n (%) |
| Bouendza       | 13 (100) | — | 1 (50) | — |
| Brazzaville    | 293 (98.32) | 5 (1.68) | 8 (38.1) | 13 (61.9) |
| Cuvette Centrale | 32 (100) | — | — | — |
| Cuvette-Ouest  | 16 (100) | — | — | 2 (100) |
| Kouilou        | 4 (100) | — | — | — |
| Lekoumou       | 12 (100) | — | — | — |
| Likouala       | 6 (100) | — | — | — |
| Niari          | 44 (100) | — | 1 (50) | 1 (50) |
| Plateau        | 22 (100) | — | — | 1 (100) |
| Pointe Noire   | 81 (100) | — | 4 (44.44) | 4 (44.44) |
| Pool           | 29 (100) | — | — | 2 (100) |
| Sangha         | 6 (100) | — | — | — |
| Total          | 558 | 5 | 14 | 24 | 1 |

*6 cases of unidentified Hb variant and 1 Hb FASD; **FSA and FSa profile.
genetic counseling of the parents of newborn babies living with sickle cell anemia [25–27].

Sickle cell trait prevalences of around 25% were obtained in some departments (Cuvette Centrale, Niari, and Pointe Noire) and 10% in others (Sangha, Likouala, Kouilou, and Bouenza). The low prevalence in these regions can be justified not only by their relatively small numbers compared to those of other departments but also by cultural habits regarding marriage.

The main abnormal Hb encountered was Hb S (97.71%) and C (0.82%). Variant C was found only in NBs with Malian parentage. This observation is similar to that made by some authors [6, 13, 14, 20, 24, 28], but differs from others in West Africa where Hb C predominates in most series 10. Indeed, Hb C is the most common abnormal Hb in West Africa and more particularly in Burkina Faso where it originated [29].

The prevalence of MSS found in our study was higher than that of our Congolese predecessors (1.35% versus 1%). The increase in prevalence is explained by the fact that 2010 study [4] was conducted in only two cities, whereas this study covered the entire country. Furthermore, the MSS profiles observed in our study were FS, FSE, and FSA, whereas they reported only one hemoglobin profile (FS). The type of equipment used in 2010 and the criteria used to define MSS could justify these differences.

In addition, MSS prevalences ranging from 0.06% to 3% have been reported in Europe, South America, Central Africa, and other countries. These variations could be justified not only by the fact that MSS is endemic in some regions while in others, it is mainly imported cases but also by the lack of knowledge of sickle cell disease in regions of high prevalence and the existence of consanguineous marriages [5–7, 9, 11, 12, 14, 15, 21, 23, 24, 28].

Similarly, the prevalence of MSS is heterogeneous within the departments of Congo. It predominates in some departments where its prevalence is higher than that observed at the national level (Table 3). Cultural habits in terms of choice of spouse, the lack of systematization of premarital screening, the mere availability of the Emmel test, and the lack of awareness in some departments could explain this disparity and, hence, the interest in setting up a capacity-building system for awareness raising, screening of couples at risk, and even genetic counseling in order to help reduce the prevalence of sickle cell disease. In addition, it will make it possible to initiate prophylaxis with penicillin therapy, which substantially reduces the morbidity and mortality of NBs [27, 30].

With regard to the sickle cell trait, as in the study by Mpemba et al., its national prevalence is 19.43%. It varies from one department to another (Table 3). In addition, we observed that the department of Cuvette Centrale, although it has a high prevalence of sickle cell trait, has fewer cases of MSS (Table 3). These facts could be justified by the health education of the population in the department. Because Cuvette Centrale is a department with an area of 48,250 km² and three general hospitals within a radius of 100 km, consanguineous marriage is prohibited. The prevalence of the sickle cell trait in our study is similar to that of some authors, who reported a prevalence of the sickle cell trait in a range of 16 to 21%. This could be justified by the fact that these countries belong to the Central African zone [4, 5, 14, 15]. In contrast, other authors in West and East Africa reported lower prevalences than ours (5 to 12%). This may be justified by the fact that these areas are far from the epicenter of sickle cell disease, which is in Central Africa [6, 10, 12, 13, 28]. Much lower prevalences (0.08 to 3.8%) are reported in European and American studies [9, 21, 23–25, 31].

In light of our observations, screening for sickle cell disease should also be systematic upstream during the premarital check-up in order to provide couples at risk with appropriate genetic counseling to guide their choice. However, it would be advisable to supplement this study with molecular biology techniques which would provide additional information on the possible presence of other haplotypes in Congo due to migration flows.

5. Conclusions

This work made it possible not only to update data on sickle cell disease in the neonatal period but also to provide epidemiological characteristics within each department of Congo. Prevalence remains stationary for the sickle cell trait, while it is increasing for major sickle cell syndromes. This resumes the frequency of homozygous and heterozygous forms of sickle cell disease in the Republic of Congo. The increase can be explained by the existence of consanguineous marriages and the absence of HbS screening tests in some regions, as well as the use of the Emmel test in other departments of Congo, although this test is less reliable. The implementation of a national program leading to systematic neonatal screening will make it possible to identify and provide early care for newborns with homozygous forms of hemoglobin S, which is a guarantee of a better quality of life, by limiting infectious and vaso-occlusive complications. The study was conducted with the aim of making neonatal screening systematic. It is a project that needs funding to be sustainable.

Data Availability

Data supporting the results of this study can be found in the attached document.

Conflicts of Interest

The authors declare no conflicts of interest in the conduct of this study.

References

[1] G. J. Kato, F. B. Piel, C. D. Reid et al., “Sickle cell disease,” Nature Reviews. Disease Primers, vol. 4, Article ID 18010, 2018.
[2] C. Hockham, S. Bhatt, R. Colah et al., “The spatial epidemiology of sickle-cell anaemia in India,” Scientific Reports, vol. 8, no. 1, Article ID 17685, 2018.
[3] M. M. Meremikwu and U. Okomo, “Sickle cell disease,” BMJ Clinical Evidence, vol. 2016, 2016.
Anemia

[4] A. Mpemba Loufoua, P. Makoumbou, and J. R. Mabiala Babela, “Dépistage Néonatal de la Drépanocytose au Congo Brazzaville,” Annales de l’Université Marien Ngouabi, vol. 11, no. 5, pp. 21–25, 2010.

[5] L. Tshilolo, L. M. Aissi, D. Lukusa et al., “Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: Experience from a pioneer project on 31 204 newborns,” Journal of Clinical Pathology, vol. 62, no. 1, pp. 35–38, 2009.

[6] M. Antoine, K. Lee, T. Donald et al., “Prevalence of sickle cell disease among Grenadian newborns,” Journal of Medical Screening, vol. 25, no. 1, pp. 49–50, 2018.

[7] R. C. Souza, P. Agnel, and D. Miranda, “Sickle cell anaemia prevalence among newborns in the Brazilian Amazon-Savanna transition region,” International Journal of Environmental Research and Public Health, vol. 16, no. 9, p. 1638, 2019.

[8] A. R. Burnham-Marusich, C. O. Ezeanolue, M. C. Obiefune et al., “Prevalence of sickle cell trait and reliability of self-reported status among expectant parents in Nigeria: implications for targeted newborn screening,” Public Health Genomics, vol. 19, no. 5, pp. 298–306, 2016.

[9] J. B. Kunz, S. Awad, M. Happich et al., “Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening,” Annals of Hematology, vol. 95, no. 3, pp. 397–402, 2016.

[10] E. Kafando, M. Sawadogo, F. Cotton, F. Vertongen, and B. Gulbis, “Neonatal screening for sickle cell disorders in Ouagadougou, Burkina Faso: a pilot study,” Journal of Medical Screening, vol. 12, no. 3, pp. 112–114, 2005.

[11] V. N. Tubman, R. Marshall, W. Jallah et al., “Newborn screening for sickle cell disease in Liberia: a pilot study,” Pediatric Blood and Cancer, vol. 63, no. 4, pp. 671–676, 2016.

[12] S. Nkya, L. Mtei, and D. Soka, “Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam,” International Health, vol. 11, no. 6, pp. 589–595, 2019.

[13] D. A. Diallo, A. Guindo, B. A. Touré et al., “Dépistage néonatal ciblé de la drépanocytose: limites du test de falciformation (test d’Emmel) dans le bilan prénatal en zone ouest africaine,” Revue d’Épidémiologie et de Santé Publique, vol. 66, no. 3, pp. 181–185, 2018.

[14] M. E. Oduvbun, A. A. Okolo, and C. M. Rahimy, “Newborn screening for sickle cell disease in a Nigerian hospital,” Public Health, vol. 122, no. 10, pp. 1111–1116, 2008.

[15] P. T. Mccann, M. G. Ferris, U. Ramamurthy et al., “A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola,” American Journal of Hematology, vol. 88, no. 12, pp. 984–989, 2013.

[16] M. Djembo-Taty, M. Tchiloemba, F. Galacteros, J. Rosa, and P. Lissouba, “[Epidemiologic study of hemoglobinopathies in the Congo in 2,257 newborn infants],” Nouvelle Revue Française d’Hematologie, vol. 28, no. 4, pp. 249–251, 1986.

[17] A. B. M. Loufoua and S. Nzingoula, “Influence de la drépanocytose sur la scolarité de l’enfant et de l’adolescent à Brazzaville,” Annales de l’Université Marien Ngouabi, vol. 8, no. 5, pp. 1–6, 2007.

[18] R Core Team, R: A Language and Environment for Statistical Computing, The European Environment Agency, Vienna, Austria, 2020.

[19] R. Munyanganizi, F. Cotton, F. Vertongen, and B. Gulbis, “Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency,” Journal of Medical Screening, vol. 13, no. 3, pp. 129–131, 2006.

[20] L. Mutesa, F. Boemer, L. Ngendahayo et al., “Neonatal screening for sickle cell disease in Central Africa: a study of 1825 newborns with a new enzyme-linked immunosorbent assay test,” Journal of Medical Screening, vol. 14, no. 3, pp. 113–116, 2007.

[21] S. Berthet, F. Monpoux, A.-M. Soummer, E. Bérard, J. Sarles, and C. Badens, “Dépistage néonatal de la drépanocytose au CHU de Nice: bilan des 8 dernières années,” Archives de Pédiatrie, vol. 17, no. 12, pp. 1652–1656, 2010.

[22] F. B. Piel, “Distribution géographique de la drépanocytose en 2010,” Médecine/Sciences, vol. 29, no. 11, pp. 965–967, 2013.

[23] R. Eller and B. Denise, “Evaluation of a neonatal screening program for sickle-cell disease,” Journal of Pediatrics, vol. 92, pp. 1–5, 2016.

[24] M. Martella, G. Viola, S. Azzena et al., “Evaluation of technical issues in a pilot multicenter newborn screening program for sickle cell disease,” International journal of neonatal screening, vol. 5, no. 1, pp. 2–8, 2019.

[25] R. Colombatti, G. Viola, and S. Schiavon, “Results of a multicenter universal newborn screening program for sickle cell disease in Italy: a call to action,” Pediatric Blood & Cancer, vol. 66, no. 5, Article ID e2765766, 2019.

[26] M. Cavazzana, A. Stanislas, and C. Rémus, “Dépistage néonatal de la drépanocytose Des données en faveur de sa généralisation,” Médecine/Sciences, vol. 34, pp. 309–311, 2018.

[27] A. Streetly, R. Risodia, and M. Dick, “Evaluation of newborn sickle cell disease screening programme in England: 2010–2016,” Archives of Disease in Childhood, vol. 103, no. 7, pp. 648–653, 2017.

[28] W. S. Silva, R. F. D. Oliveira, S. B. Ribeiro, I. B. da Silva, E. M. de Araújo, and A. F. Baptista, “Screening for structural hemoglobin variants,” International Journal of Environmental Research and Public Health, pp. 13–18, 2016.

[29] J. Ayéroué, E. Kafando, and L. Kam, “Le syndrome drépanocytaire de type hémoglobine SC: expérience du CHU Yalgado Ouédraogo de Ouagadougou (Burkina Faso),” Archives de Pédatrie, vol. 16, no. 4, pp. 316–321, 2009.

[30] M. De Montalembert and L. Tshilolo, “Is therapeutic progress reported status among expectant parents in Nigeria: implications for targeted newborn screening,” Public Health Genomics, vol. 12, no. 3, pp. 112–114, 2005.

[31] R. Eller and B. Denise, “Evaluation of a neonatal screening program for sickle-cell disease,” International Journal of Environmental Research and Public Health, vol. 11, no. 6, pp. 589–595, 2019.

[32] A. M. Grant, “Emergency department visits made by patients with sickle cell disease,” American Journal of Preventive Medicine, vol. 38, no. 4, pp. S536–S541, 2010.

[33] R. Eller and B. Denise, “Evaluation of a neonatal screening program for sickle-cell disease,” International Journal of Environmental Research and Public Health, vol. 92, pp. 309–311, 2018.

[34] A. M. Grant, “Emergency department visits made by patients with sickle cell disease,” American Journal of Preventive Medicine, vol. 38, no. 4, pp. S536–S541, 2010.